An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
DC vaccine primes EBV-specific CD8+ T cells that recognize LMP2A peptides presented on MHC I and kill target cells via perforin/granzyme-mediated cytolysis (and Fas/FasL apoptosis).
Anti-BCMA antibody–drug conjugate that delivers the microtubule inhibitor MMAF; binds BCMA, is internalized, disrupts microtubules to kill malignant plasma cells, and also mediates ADCC/ADCP.
Afucosylated anti-BCMA antibody–drug conjugate linked to MMAF (auristatin). Binds BCMA on malignant plasma cells, is internalized, and delivers MMAF to inhibit tubulin polymerization causing G2/M arrest and apoptosis; Fc afucosylation enhances ADCC/ADCP.
YES
DIRECT
Belantamab mafodotin binds BCMA, is internalized, and delivers the MMAF auristatin payload to inhibit tubulin polymerization, causing G2/M arrest and apoptosis; its afucosylated Fc also enhances ADCC/ADCP.
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
Vaccine-primed EBV-specific CD8+ T cells recognize LMP2B-derived peptides on MHC I of EBV+ cells and kill them via perforin/granzyme-mediated cytolysis (with CD4+ T-cell help).
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
DC vaccine primes/expands EBV-specific T cells; these T cells recognize EBNA1-derived peptides on MHC and kill EBNA1+ cells via perforin/granzyme-mediated cytolysis.
An autologous monocyte-derived dendritic cell vaccine pulsed with Epstein–Barr virus (EBV)-associated antigens. The ex vivo–generated dendritic cells present EBV antigens via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-γ production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
Autologous monocyte-derived dendritic cells pulsed with EBV antigens present peptides via MHC I/II to prime and expand EBV-specific CD8+ cytotoxic and CD4+ helper T cells, enhancing IFN-gamma production and perforin/granzyme-mediated killing of EBV-positive lymphoma cells.
YES
INDIRECT
DC vaccine primes/expands EBV-specific CD8+ T cells, which recognize EBNA2-derived peptides on MHC I of EBV+ cells and kill them via perforin/granzyme-mediated cytotoxicity.